Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1L | O00429 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21875245 | 0.91 | DNM1L (0.82) | DNM1L | |
| SCHEMBL21875348 | 0.89 | DNM1L (0.81) | DNM1L | |
| SCHEMBL21875331 | 0.89 | DNM1L (0.81) | DNM1L | |
| SCHEMBL21875325 | 0.89 | DNM1L (1.00) | DNM1L | |
| SCHEMBL21875244 | 0.89 | DNM1L (1.00) | DNM1L | |
| SCHEMBL21875365 | 0.89 | DNM1L (0.82) | DNM1L | |
| SCHEMBL21875315 | 0.89 | DNM1L (1.00) | DNM1L | |
| SCHEMBL21875259 | 0.88 | DNM1L (1.00) | DNM1L | |
| SCHEMBL21875287 | 0.88 | DNM1L (1.00) | DNM1L | |
| SCHEMBL21875307 | 0.87 | DNM1L (1.00) | DNM1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168080-B2 | Dynamin-1-like protein inhibitors | MITOBRIDGE, INC. (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200131172-A1 | DYNAMIN-1-LIKE PROTEIN INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2020-04-30 | — | — | US | disclosed |
| US-20200131172-A1 | DYNAMIN-1-LIKE PROTEIN INHIBITORS | Astellas Engineered Small Molecules US, Incorporated | 2020-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11168080-B2 | Dynamin-1-like protein inhibitors | DNM1L, DNM1, DNM2 | DNM1L 1/4885 |
| US-20200131172-A1 | DYNAMIN-1-LIKE PROTEIN INHIBITORS | DNM1L, DNM1, DNM2 | DNM1L 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.